Jesper D. Gunst

@EATGx @HIVGlasgow It was a pleasure to be part of this workshop. Thank you!

Thank you to the #STEPS 10 workshop faculty and all attendees! #EATGatHIVGlasgow2024

🚨 We’re hiring! 🚨 Join the Gaebler & Ibrahim Labs for an exciting postdoc position at the intersection of virology & gene regulation! Help us uncover mechanisms behind HIV latency using cutting-edge genome engineering. More info: nature.com/naturecareers/…

Exciting news! Our survey report with @ECDC_EU on #HIV #stigma in the #healthcare setting is now available. Huge thanks to everyone who contributed to its success! 👉bit.ly/46kI1uN Don't miss the presentation on Friday by @TeyNoori at #AIDS2024

@JillianLau1 Haha! I try to follow you, but I can’t keep up 🥳

@JesperGunst Knew you would have my back @JesperGunst !

Track A session at #AIDS2024 on timing of #HIVcure interventions chaired by Ole Sogaaard. it’s great to see summary slides in these sessions! First up @_GabrielDuette presented on participants in the PULSE (hydroxyurea) study w/ ⬆️ HIV immune responses post multiple ATIs

@JillianLau1 Time to detectable viremia = first pVL >50 copies/ml Time to loss of virologic control = ART restart or two consecutive pVL >= 5,000 copies/ml 👌🏻

Vibeke Klastrup: reservoir size & type of intervention predict loss of virologic control in review of Danish #ATI #HIVcure trials incl TITAN ROADMAP & eCLEAR( bNAbs, HDACi, & TLRa. I’m confused abt what the difference between time to viral rebound v loss of control is here.

Vibeke Klastrup presenting metanalysis of ATI studies showing smaller reservoir size and interventions such as #bNAbs are associated with duration of viral control during treatment interruptions. #AIDS2024

@tristanjbarber @sandulescu_oana @MartaVasylyev @NachoBernardino @AgnesLibois @MariaMazzitell4 @EACSociety Fantastic!

How to interpret and how to manage low level viremia? Hearing now from @JesperGunst with important insight from amazing session chair @Rokx1 at #YINGconf24

Onto my fave topic - analytical treatment interruptions: where ART is stopped in an #HIVcure study. Viral rebound. Tongcui Ma showed T cell features (pic 1) and Mauro Garcia showed IgG antibodies (pic 2) impacted time to viral rebound. Use as biomarkers for TVR? #CROI2024

@JillianLau1 Thanks, Jill 🤟🏻

#CROI2024 Great poster (512) from @JesperGunst on sensitivity testing for bNAbs. Very topical & challenging! Analysis from eCLEAR (3BNC117 & romidepsin + ART initiation) in ART naive people - 3 methods of sensitivity testing. Most sensitive was the slope on the PhenoSense assay

The survey on "Measuring #HIV knowledge and attitudes in the #healthcare setting" is still available until 5 Dec! Complete it today or spread the word in your network. 🔄 Available in 38+ languages! 🌍 Survey link: ow.ly/w7vH50QcPWv @ECDC_EU

@c_gaebler @ChariteBerlin Congrats, Christian! 👌🏻

Honored to announce my appointment as Professor for Translational Immunology of Viral Infections at @ChariteBerlin! Joining my Alma Mater's faculty is an incredible privilege, and I'm excited to contribute to the fantastic research community at this historic institution.

Editorial: “Host Receptor Targeting to Treat #Covid19” by @JesperGunst and Ole Schmeltz Søgaard eviden.cc/3ScIr1C #SARSCov2 #InfectiousDisease @AarhusUni_int @AUHdk @syctong @Josh_S_Davis @jasonroberts_pk

If you work in a healthcare setting in Europe or Central Asia, you are invited to take this survey on stigma & discrimination by @ECDC_EU and @EACSociety ⏲️ Deadline: 30 November 2023 #StigmaFree

Inhibition of intracellular enzymes like TMPRSS2 that are vital for replication of #SARSCoV2 may be an effective treatment strategy for #COVID19. Gunst and Sogaard comment on recent clinical evidence for the effect of TMPRSS2 inhibitors like nafamostat. eviden.cc/3ScIr1C

Exciting news! The Berlin Institute of Health at Charité @berlinnovation is launching its BIH PhD Program, focused on medical translation and innovation. 🌟 Fully funded doctoral positions for translational projects 🌟 Open for applications until Nov 22 bihealth.org/en/notices/bih…

@ECDC_EU @ECDC_HIVAIDS @EACSociety

European AIDS Clinical Society (EACS) vil undersøge viden og holdninger om HIV blandt sundhedsfaglige på tværs af Europa. Så hvis du har ca. 10 min til at udfylde - vil vi blive glade! @Sygeplejeraadet @laegeforeningen @Sundpol @regionerne eacsociety.org/activities/eac…

In people with HIV-1 undergoing antiretroviral treatment interruption, lefitolimod + broadly neutralizing antibodies did not delay viral rebound more than antibodies alone, raising questions of how to optimize combination immunotherapy to control HIV-1 nature.com/articles/s4159…

Review on Immunomodulation with IL-7 and IL-15 in #HIV-1 infection. @viruseradicate sciencedirect.com/science/articl…